Kristina Etheridge
Endocrinology, Diabetes & Metabolism · Dallas, TXNPI 1730987819
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 96 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 22.8% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in TX, where the typical reported total is $2,974.
Across 96 payments — averaging $23.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$514
- Madrigal Pharmaceuticals$297
- Novo Nordisk$208
- Sequel Med Tech, LLC$204
- Xeris Pharmaceuticals, Inc.$149
- Amgen$120
- plus $768 from 17 others
What the payments were for
- Food & beverage$2,261100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 12 | $514 |
| Madrigal Pharmaceuticals | 15 | $297 |
| Novo Nordisk | 9 | $208 |
| Sequel Med Tech, LLC | 7 | $204 |
| Xeris Pharmaceuticals, Inc. | 9 | $149 |
| Amgen | 6 | $120 |
| Bayer | 6 | $118 |
| Sanofi-aventis U.S. LLC | 4 | $91 |
| Tandem Diabetes Care, Inc. | 4 | $72 |
| Mannkind Corporation | 2 | $72 |
| Boehringer Ingelheim | 3 | $55 |
| Astellas Pharma US Inc | 3 | $51 |
| Lilly USA, LLC | 3 | $50 |
| Dexcom, Inc. | 3 | $48 |
| Ascendis Pharma Endocrinology Inc | 2 | $42 |
| Soleno Therapeutics, Inc. | 1 | $30 |
| AstraZeneca | 1 | $26 |
| Amneal Pharmaceuticals LLC | 1 | $24 |
| Insulet Corporation | 1 | $20 |
| Tolmar, Inc. | 1 | $20 |
| AbbVie | 1 | $18 |
| Amphastar Pharmaceuticals, Inc. | 1 | $16 |
| Corcept Therapeutics | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$278
How this compares
$2,261 in reported general payments places this provider in the 45th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Other endocrinology, diabetes & metabolism in Dallas
- Pablo MoraDallas$1.3M
- Steve FordanDallas$1.2M
- Saleemah FahmiDallas$1.2M
- Julio RosenstockDallas$1.2M
- Ildiko LingvayDallas$711K
- Rajiv DattatreyaDallas$437K
- Jaime AlmandozDallas$334K
- Luigi MeneghiniDallas$136K
- Oksana HamidiDallas$106K
- Lance SloanLufkin$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.